Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline

Ray E. Hershberger, Michael M. Givertz, Carolyn Y. Ho, Daniel P. Judge, Paul F. Kantor, Kim L. McBride, Ana Morales, Matthew R.G. Taylor, Matteo Vatta, Stephanie Ware

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This guideline describes the approach and expertise needed for the genetic evaluation of cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the guideline has now been updated in collaboration with the American College of Medical Genetics and Genomics (ACMG). The writing group, composed of cardiologists and genetics professionals with expertise in adult and pediatric cardiomyopathy, reflects the emergence and increased clinical activity devoted to cardiovascular genetic medicine. The genetic evaluation of cardiomyopathy is a rapidly emerging key clinical priority, because high-throughput sequencing is now feasible for clinical testing and conventional interventions can improve survival, reduce morbidity, and enhance quality of life. Moreover, specific interventions may be guided by genetic analysis. A systematic approach is recommended: always a comprehensive family history; an expert phenotypic evaluation of the proband and at-risk family members to confirm a diagnosis and guide genetic test selection and interpretation; referral to expert centers as needed; genetic testing, with pre- and post-test genetic counseling; and specific guidance as indicated for drug and device therapies. The evaluation of infants and children demands special expertise. The approach to managing secondary and incidental sequence findings as recommended by the ACMG is provided.

Original languageEnglish (US)
Pages (from-to)281-302
Number of pages22
JournalJournal of Cardiac Failure
Volume24
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Practice Guidelines
Cardiomyopathies
Genomics
Guidelines
Incidental Findings
Genetic Counseling
Medical Genetics
Genetic Testing
Referral and Consultation
Quality of Life
Medicine
Pediatrics
Morbidity
Drug Therapy
Equipment and Supplies

Keywords

  • Cardiomyopathy
  • genetic analysis
  • genetics
  • practice guideline
  • secondary findings

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hershberger, R. E., Givertz, M. M., Ho, C. Y., Judge, D. P., Kantor, P. F., McBride, K. L., ... Ware, S. (2018). Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. Journal of Cardiac Failure, 24(5), 281-302. https://doi.org/10.1016/j.cardfail.2018.03.004

Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. / Hershberger, Ray E.; Givertz, Michael M.; Ho, Carolyn Y.; Judge, Daniel P.; Kantor, Paul F.; McBride, Kim L.; Morales, Ana; Taylor, Matthew R.G.; Vatta, Matteo; Ware, Stephanie.

In: Journal of Cardiac Failure, Vol. 24, No. 5, 01.05.2018, p. 281-302.

Research output: Contribution to journalArticle

Hershberger, RE, Givertz, MM, Ho, CY, Judge, DP, Kantor, PF, McBride, KL, Morales, A, Taylor, MRG, Vatta, M & Ware, S 2018, 'Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline', Journal of Cardiac Failure, vol. 24, no. 5, pp. 281-302. https://doi.org/10.1016/j.cardfail.2018.03.004
Hershberger, Ray E. ; Givertz, Michael M. ; Ho, Carolyn Y. ; Judge, Daniel P. ; Kantor, Paul F. ; McBride, Kim L. ; Morales, Ana ; Taylor, Matthew R.G. ; Vatta, Matteo ; Ware, Stephanie. / Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. In: Journal of Cardiac Failure. 2018 ; Vol. 24, No. 5. pp. 281-302.
@article{f04472d66f734c8e97e64663c894f77b,
title = "Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline",
abstract = "This guideline describes the approach and expertise needed for the genetic evaluation of cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the guideline has now been updated in collaboration with the American College of Medical Genetics and Genomics (ACMG). The writing group, composed of cardiologists and genetics professionals with expertise in adult and pediatric cardiomyopathy, reflects the emergence and increased clinical activity devoted to cardiovascular genetic medicine. The genetic evaluation of cardiomyopathy is a rapidly emerging key clinical priority, because high-throughput sequencing is now feasible for clinical testing and conventional interventions can improve survival, reduce morbidity, and enhance quality of life. Moreover, specific interventions may be guided by genetic analysis. A systematic approach is recommended: always a comprehensive family history; an expert phenotypic evaluation of the proband and at-risk family members to confirm a diagnosis and guide genetic test selection and interpretation; referral to expert centers as needed; genetic testing, with pre- and post-test genetic counseling; and specific guidance as indicated for drug and device therapies. The evaluation of infants and children demands special expertise. The approach to managing secondary and incidental sequence findings as recommended by the ACMG is provided.",
keywords = "Cardiomyopathy, genetic analysis, genetics, practice guideline, secondary findings",
author = "Hershberger, {Ray E.} and Givertz, {Michael M.} and Ho, {Carolyn Y.} and Judge, {Daniel P.} and Kantor, {Paul F.} and McBride, {Kim L.} and Ana Morales and Taylor, {Matthew R.G.} and Matteo Vatta and Stephanie Ware",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.cardfail.2018.03.004",
language = "English (US)",
volume = "24",
pages = "281--302",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline

AU - Hershberger, Ray E.

AU - Givertz, Michael M.

AU - Ho, Carolyn Y.

AU - Judge, Daniel P.

AU - Kantor, Paul F.

AU - McBride, Kim L.

AU - Morales, Ana

AU - Taylor, Matthew R.G.

AU - Vatta, Matteo

AU - Ware, Stephanie

PY - 2018/5/1

Y1 - 2018/5/1

N2 - This guideline describes the approach and expertise needed for the genetic evaluation of cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the guideline has now been updated in collaboration with the American College of Medical Genetics and Genomics (ACMG). The writing group, composed of cardiologists and genetics professionals with expertise in adult and pediatric cardiomyopathy, reflects the emergence and increased clinical activity devoted to cardiovascular genetic medicine. The genetic evaluation of cardiomyopathy is a rapidly emerging key clinical priority, because high-throughput sequencing is now feasible for clinical testing and conventional interventions can improve survival, reduce morbidity, and enhance quality of life. Moreover, specific interventions may be guided by genetic analysis. A systematic approach is recommended: always a comprehensive family history; an expert phenotypic evaluation of the proband and at-risk family members to confirm a diagnosis and guide genetic test selection and interpretation; referral to expert centers as needed; genetic testing, with pre- and post-test genetic counseling; and specific guidance as indicated for drug and device therapies. The evaluation of infants and children demands special expertise. The approach to managing secondary and incidental sequence findings as recommended by the ACMG is provided.

AB - This guideline describes the approach and expertise needed for the genetic evaluation of cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the guideline has now been updated in collaboration with the American College of Medical Genetics and Genomics (ACMG). The writing group, composed of cardiologists and genetics professionals with expertise in adult and pediatric cardiomyopathy, reflects the emergence and increased clinical activity devoted to cardiovascular genetic medicine. The genetic evaluation of cardiomyopathy is a rapidly emerging key clinical priority, because high-throughput sequencing is now feasible for clinical testing and conventional interventions can improve survival, reduce morbidity, and enhance quality of life. Moreover, specific interventions may be guided by genetic analysis. A systematic approach is recommended: always a comprehensive family history; an expert phenotypic evaluation of the proband and at-risk family members to confirm a diagnosis and guide genetic test selection and interpretation; referral to expert centers as needed; genetic testing, with pre- and post-test genetic counseling; and specific guidance as indicated for drug and device therapies. The evaluation of infants and children demands special expertise. The approach to managing secondary and incidental sequence findings as recommended by the ACMG is provided.

KW - Cardiomyopathy

KW - genetic analysis

KW - genetics

KW - practice guideline

KW - secondary findings

UR - http://www.scopus.com/inward/record.url?scp=85046832864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046832864&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2018.03.004

DO - 10.1016/j.cardfail.2018.03.004

M3 - Article

C2 - 29567486

AN - SCOPUS:85046832864

VL - 24

SP - 281

EP - 302

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 5

ER -